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Abstract
Bovine herpesvirus type 1 (BHV-1) UL49.5 inhibits transporter associated with antigen processing (TAP) and down-regulates
cell-surface expression of major histocompatibility complex (MHC) class I molecules to promote immune evasion. We have
constructed a BHV-1 UL49.5 cytoplasmic tail (CT) null and several UL49.5 luminal domain mutants in the backbone of wild-
type BHV-1 or BHV-1 UL49.5 CT- null viruses and determined their relative TAP mediated peptide transport inhibition and
MHC-1 down-regulation properties compared with BHV-1 wt. Based on our results, the UL49.5 luminal domain residues 30–
32 and UL49.5 CT residues, together, promote efficient TAP inhibition and MHC-I down-regulation functions. In vitro, BHV-1
UL49.5 D30–32 CT-null virus growth property was similar to that of BHV-1 wt and like the wt UL49.5, the mutant UL49.5 was
incorporated in the virion envelope and it formed a complex with gM in the infected cells.
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Introduction
Bovine herpesvirus-1 (BHV-1) is an important cattle pathogen
responsible for a wide variety of clinical diseases, including
conjunctivitis and upper respiratory tract infection known as
infectious bovine rhinotracheitis (IBR), reproductive tract lesions
and abortion in pregnant cows, and systemic infection in the
newborn [1,2,3]. In addition, BHV-1 has been recognized as an
important component of the bovine respiratory disease (BRD)
complex [3,4]. Normally, proteosomally processed viral proteins
yield peptides that bind to TAP heterodimer, consisting of the
subunits TAP1 and TAP2 [5,6,7]. Following viral peptide binding,
the TAP1/TAP2 heterodimer undergoes conformational changes
[5,6,7]. Subsequently, peptides are transported into the ER and
loaded onto MHC-I molecules to form MHC/peptide complexes
which are transported to and presented on the cell surface [8,9].
However, in BHV-1-infected cells, UL49.5 (BHV-1 homolog of
envelope glycoprotein gN) binds to TAP, interferes with its peptide
transport function and also degrades the TAP [10,11]. Conse-
quently, BHV-1 interferes with the MHC class I antigen pre-
sentation pathway and during the initial phase of viral infection,
escapes host cellular immune surveillance and elimination [11–15].
Modified live vaccines (MLV) against BHV-1 including genetically
engineered gE-deleted marker vaccines are being used for
vaccination against BHV-1. However, problems associated with
BHV-1 infection in the vaccinated animals exist, especially in the
feedlot. Since both the traditional and gE-deleted MLVs have wild-
type UL49.5, these vaccines like the wild-type virus, are transiently
immunosuppressive. Therefore, there is a need for further impro-
vement of the current MLVs [16–19].
Alphaherpesvirus UL49.5 (gN) and gM homologs are associated
with cellular and virion membranes and the gN homologs form
complexes with envelope glycoprotein gM [20–22]. BHV-1 UL49.5
predicted ORF (Fig. 1A) is composed of an N-terminal signal
sequence of 22 amino acids (aa), an extracellular luminal domain of
32 aa, a transmembrane (TM) domain of 25 aa, and a short
cytoplasmic tail (CT) of 17 aa [10,22,23]. Previous results have
shown that a BHV-1 UL49.5 CT-truncated virus lacking the
cytosolic 17 amino acids no longer degraded bovine TAP molecules
yet retained the TAP inhibition and MHC-I down-regulation
functions[15].ThissuggeststhattheBHV-1UL49.5luminaldomain
or TM domain is associated with the TAP inhibition function.
Recently, using N-terminal and C-terminal truncated versions
of BHV-1 UL49.5 expressed in a Baculovirus expression vector
system, it was shown that UL49.5 luminal domain residues 23–32
and UL49.5 cytoplasmic tail residues 94–96 are both essential for
UL49.5-mediated degradation of human TAP [24]. However,
UL49.5 luminal domain residues 28–32 alone are sufficient for
human TAP inhibition and down-regulation of human MHC-I
surface expression [24]. The goal for this study was to i) identify
the exact UL49.5 residues critical for bovine TAP inhibition and
bovine MHC-I down-regulation in the context of BHV-1 virus-
infected Madin-Darby bovine kidney (MDBK) cells, and ii)
determine the effect of UL49.5 mutations on UL49.5/gM complex
formation and gM processing. We constructed BHV-1 UL49.5
luminal domain mutants, with a short sequence deletion, using a
BHV-1 UL49.5 cytoplasmic tail (CT) null virus or wt BHV-1 as a
backbone and analyzed their TAP inhibition and MHC-I
molecule surface expression properties in infected MDBK cells
relative to wt BHV-1. The results demonstrate that UL49.5
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25742residues 30 to 32 are essential for the BHV-1 UL49.5-mediated
TAP inhibition/MHC-I down-regulation function. However,
UL49.5 CT residues are required for efficient TAP inhibition/
MHC-I down-regulation. The mutant UL49.5 lacking luminal
domain residues 30–32 and the entire cytoplasmic tail is
incorporated in the virion envelope and it formed a complex with
gM in the infected cells.
Materials and Methods
Cells and virus strain
The MDBK cell line was maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 5–10% heat-
inactivated fetal bovine serum (FBS). The BHV-1 Cooper
(Colorado-1) strain, obtained from the American Type Culture
Collection (Manassas, VA) was propagated and titrated in MDBK
cells as previously described [25].
Plasmids and bacterial strains
Vector pGEX-4T-2 (GE healthcare) and E. coli strain BL21
were used to express BHV-1 UL49.5-GST or bovine TAP1-GST
fusion proteins. E. coli strain DH10B was used to maintain all the
infectious BHV-1 BAC clones. E. coli strain SW105 (kindly
provided by Dr. Copeland) was used for Red recombination.
Antibodies
Chicken anti-Calreticulin (ER) polyclonal Ab (ab14234,
Abcam), biotinylated donkey anti-rabbit IgG (ab6801, Abcam),
HRP-conjugated donkey anti-rabbit IgG (Cat. 31458, Thermo),
phycoerytrin (PE)-conjugated donkey anti-goat antibody (F0107,
R&D), Alexa Flour (350)-conjugated donkey anti-chicken Ab
(Invitrogen), Alexa flour 488-conjugated donkey anti-goat Ab
(Molecular Probes), Alexa flour 594-conjugated donkey anti-rabbit
Ab (Molecular Probes), mouse anti-MHC I Ab (H58A, VMRD),
and FITC-conjugated rat anti-mouse IgG (ebioscience) were
purchased from the respective commercial sources.
Production of anti-BHV-1 UL49.5-, gM- and anti-bovine
TAP1-specific polyclonal sera
i) Anti-BHV-1 gM-specific antibody. A peptide
corresponding to the predicted amino acid (aa) residues 191–205
([H]-QAVHALRERSPRAHRC-OH) of BHV-1 gM was synthesized
and conjugated to polyethylene glycol as described earlier [26] [27]
and used to immunize New Zealand white rabbits (Cocalico
Biologicals) to generate anti-BHV-1 gM serum.
ii) Anti-BHV-1 UL49.5-specific antibody. The DNA
fragment corresponding to UL49.5 amino acid residues 23 to
60 (Genbank Accession No. AJ004801) was cloned into pGEX-
4T-2 vector and expressed in E. coli BL21 as a GST fusion protein.
The UL49.5-specific peptide was purified using a glutathione-
sepharose column followed by thrombin protease cleavage and
used to immunize rabbits (Cocalico Biologicals) as described
earlier [27].
iii) Anti-bovine TAP1-specific antibody. The predicted
amino acid residues 117 to 167 and residues 351 to 415 (Accession
No. AAY34698) of bovine TAP1 were amplified by PCR, cloned
Figure 1. Predicted amino acid (aa) sequences of BHV-1 UL49.5 ORF. The bold italic letters indicate UL49.5 cytoplasmic tail residues (A).
Alignment of BHV-1 UL49.5 luminal domain aa sequences with UL49.5 homologues of equine herpesvirus 1 (EHV-1; ref. or Genbank accession #), EHV-
4, psueudorabiesvirus (PRV) and canine herpesvirus (CHV) (B). Identical aa residues are bolded. Schematic illustration of BHV-1 UL49.5 luminal domain
mutants with a short sequence deletion or alanine substitutions using the BHV-1 UL49.5 CT-null (C) or BHV-1 wt as a backbone (D).
doi:10.1371/journal.pone.0025742.g001
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purified to immunize rabbits and goats as described above.
Cell transfection and generation of UL49.5 expressing cell
line
To generate a UL49.5 expressing cell line, first the entire BHV-1
UL49.5 ORF coding region was amplified from the wild type
BHV-1 Cooper strain genomic DNA by PCR and cloned into the
eukaryotic expression vector, pEF6/V5-His TOPO (Invitrogen).
Positive clones containing UL49.5-specific sequences were identi-
fied by PCR and sequencing of the UL49.5 ORF coding region.
One positive UL49.5-pEF6/V5-His clone DNA was transfected
into MDBK cells by Lipofectamine (Invitrogen) as described
earlier [27]. Forty-eight hours after transfection, confluent cells
were treated with trypsin and diluted 5-fold in DMEM containing
10 mg/ml of Blastcidin (Invitrogen) and plated in 25 cm
2 flasks.
The Blastcidin concentration was decreased to 5 mg/ml after 7
days, and thereafter the medium was replaced every 3 days until
the distinct Blasticidin-resistant colonies developed. Blastcidin-
resistant clones were then isolated and analyzed for UL49.5
expression by indirect immunofluorescence (IF) and immunopre-
cipitation assays (Fig. S2).
Radiolabelling of mock- or virus-infected MDBK cell
proteins, SDS-PAGE and immunoprecipitation/
immunoblotting analysis
[
35S] methionine-cysteine labeling of the mock- or virus-infected
MDBK cells was performed as described earlier [28,29]. Cell
lysates and immunoprecipitates were denatured at 100uCi n
reducing sample buffer containing b-mercapthoethanol for the
UL49.5 samples, and separated in a 5,20% linear gradient
sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) [23].
However, for gM and TAP1 analyses, cell lysates and immuno-
precipitates were incubated at 56uC in reducing sample buffer
with 100 mM Dithiothreitol (DTT) and then loaded on a 5,20%
linear gradient or 10% SDS-PAGE respectively [22,23,28].
Construction of BHV-1 UL49.5 cytoplasmic tail null virus
(BHV-1 UL49.5 CT-null BAC)
We followed a two-step Red-mediated mutagenesis protocol as
described earlier by Tischer et al [30] to construct a UL49.5
cytoplasmic tail null virus. Briefly, primers for UL49.5-CT null-
forward (for) and UL49.5-CT null-reverse (rev) were designed to
delete 7 nucleotides (nt) of UL49.5 ORF (238 to 244, AGGCTCA)
and to mutate the nt 246–247 (GG) to AA (Fig. S1, table 1). The
PCR amplified I-SceI/aphAI cassette was digested with Dpn I,
purified and electroporated together with pBAD-I-SceI DNA into
SW105 competent cells harboring pBHV-1 WT BAC for 1
st
recombination as described earlier [30,31,32]. Several kanamycin-
sensitive colonies were obtained after the 2
nd recombination.
Finally, positive pBHV-1 BAC UL49.5 CT-null colonies were
identified by PCR and sequencing of the UL49.5 ORF in the
putative mutant colonies. The BAC-excised BHV-1 UL49.5
CT-null virus was generated from a pBHV-1 BAC UL49.5
CT-null clone by Cre-mediated BAC excision as described earlier
[30–32].
BAC mutagenesis to incorporate short deletions or
alanine substitutions within UL49.5 luminal domain
As shown in Table 1, primer pairs specific for short sequence
deletion at UL49.5 amino acid residues 30 to 32 (UL49.5D30–32),
37 to 40 (UL49.5D37–40), and 43 to 46 (UL49.5D43–46) or
alanine substitutions at residues 30 to 32 (UL49.5 30AAA32) were
synthesized. The PCR products were amplified, purified, and
electroporated into the SW105 competent cells harboring pBHV-1
BAC (wt) or pBHV-1 BAC UL49.5 CT-null for 1
st recombination,
and 2
nd recombination was performed as described above.
Reconstituted BAC containing or BAC-excised mutant viruses
were then generated as described earlier [30,31,32]. BAC-excised
UL49.5 mutant viruses were plaque purified and designated as
BHV-1UL49.5D30–32, UL49.5 30AAA32, UL49.5D30–32 CT-
null, UL49.5 30AAA32 CT-null, UL49.5D37–40 CT-null, and
UL49.5D43–46 CT-null, respectively.
Table 1. PCR primers used for generation of BHV-1 UL 49.5 mutants and for colony identification.
Primer Sequence (59 to 39)
Mutagenesis
a
CT-null for 59-AATGGTCGCCGTGGCCCTGTACGCGTACGGGCTTTGCTTTTAAGCGCCAGCGGGCCCAATaggatgacgacgataagtaggg-39
CT-null Rev 59-CGCCCCCGCGACTCCTTTTTATTGGGCCCGCTGGCGCTTAAAAGCAAAGCCCGTACGCGTcaaccaattaaccaattctgattag-39
D30–32 for 59-TGCCATCGTGCGCGGCCGCGACCCCCTGCTAGACGCGATGGGGGCAATGGACTTTTGGAGaggatgacgacgataagtaggg-39
D30–32 rev 59-CGCGCGCGTAGCAGCCTGCGCTCCAAAAGTCCATTGCCCCCATCGCGTCTAGCAGGGGGTcaaccaattaaccaattctgattag-39
D37–40 for 59-ACCCCCTGCTAGACGCGATGCGGCGCGAGGGGGCAATGGACGGCTGCTACGCGCGCGGGGTaggatgacgacgataagtaggg-39
D37–40 rev 59-GCGGTGGCTCCGAGAGCGGCACCCCGCGCGCGTAGCAGCCGTCCATTGCCCCCTCGCGCCcaaccaattaaccaattctgattag-39
D43–46 for 59-ATGCGGCGCGAGGGGGCAATGGACTTTTGGAGCGCAGGCTGCGTGCCGCTCTCGGAGCCACCaggatgacgacgataagtaggg-39
D43–46 rev 59-TAAAAAACAACCAGGGCCTGCGGTGGCTCCGAGAGCGGCACGCAGCCTGCGCTCCAAAAGTcaaccaattaaccaattctgattag-39
30aaa32 Fo 59-TGCCATCGTGCGCGGCCGCGACCCCCTGCTAGACGCGATGgcggccgcgGGGGCAATGGACTTTTGGAGaggatgacgacgataagtaggg-39
30aaa32 Re 59-CGCGCGCGTAGCAGCCTGCGCTCCAAAAGTCCATTGCCCCcgcggccgcCATCGCGTCTAGCAGGGGGTcaaccaattaaccaattctgattag-39
Colony PCR
b
UL 49.5 forward agagcgccagcgagtcgggctc d30–32 SRe agtccattgccccCTCGCGCCG
d37–40 SRe gcgcgcgtagcagccTGCGCT d43–46 SRe ctccgagagcggcacCCCGC
aBHV-1 UL 49.5-specific sequences are shown in uppercase letter; the italicized and italicized-underlined sequences are complementary to each other in reverse
orientation. Nucleotides in lowercase indicate the pEPkan-S-specific sequences.
bPrimers used for identification of BHV-1 UL 49.5 mutants from selected kanamycin-sensitive colonies by PCR. The bold letters indicate the complementary sequences, in
reverse orientation, corresponding to the deleted UL 49.5 nucleotides.
doi:10.1371/journal.pone.0025742.t001
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One step growth curve assays were performed as described
earlier [25,33]. Average plaque size was calculated by measuring
50 randomly selected plaques for each mutant virus (under a
microscope with a graduated ocular objective).
TAP1 and UL49.5 intracellular staining and laser scanning
confocal microscopy
MDBK cells grown on permanox chamber slides (Cole-Parmer)
were infected with wt BHV-1 or BHV-1 UL49.5mutantviruses.Cells
were fixed at different times post-infection with freshly prepared 1%
paraformaldehyde in PBS, permeabilized with FACS permeabilizing
solution, and blocked with 2% IgG free bovine serum albumin. The
cells were incubated (for 60 minutes) with a cocktail of goat anti-
bovine TAP 1 (1:800), rabbit anti-UL49.5 (1:3,200) and chicken anti-
calreticulin (ER) antibodies (1:3,200), washed and subsequently
stained (for 15 min) with a cocktail of Alexa flour 488-conjugated
donkey anti-goat (1:2,000), Alexa 350-conjugated donkey anti-
chicken (1:2,000), and Alexa flour 594-conjugated donkey anti-rabbit
antibodies (1:2,000). After 5 washes, coverslips were mounted onto
slides and examined with a Zeiss LSM510 laser scanning confocal
microscopy using 206 and 406 objectives. Cellular ER-, bovine
TAP1- and UL49.5-specific labeling was excited at laser wavelengths
of 410 nm, 517 nm, and 617 nm respectively.
Analysis of peptide transport in the BHV-1 UL49.5
mutants-infected cells
MDBK cells grown on 6-well plate were infected at a MOI of
10 with BHV-1 wt, BHV-1 UL49.5 CT-null and various UL49.5
luminal domain mutant viruses. At different time-points (2, 5, and
8 hpi), the cells were trypsinized, permeabilized, and incubated
with 5 ml of Phycoerythrin-conjugated mouse anti-calreticulin
(anti-ER) MAb (Clone FMC 75, Abcam) and the FITC-
conjugated synthetic peptide, SVNKTERAY, in the absence
and presence of ATP (10 mM, Sigma) for 20 min at 37uC in the
dark [11,34]. The cells were fixed after three washes and analyzed
for fluorescence intensity by a FACS Calibur flow cytometer. At
least 30,000 gated events based on forward and side scatters and
pulse width were analyzed using Summit Data Acquisition and
Analysis software (DakoCytomation). The mock infected MDBK
cells served as a control.
Detection of MHC-I expression on the infected cell
surface by FACS
Approx. 10
6 of MDBK cells either mock infected or infected (1
MOI)with BHV-1wt,BHV-1UL49.5 CT-null,orindividual BHV-
1 mutant virus were collected at 12 or 18 hpi, blocked with IgG free
BSA, and incubated (for 20 min) with mouse anti-bovine MHC I
Ab. After PBS washes, cells were incubated with 5 ml of FITC-
conjugated rat anti-mouse Ab and fixed with 2% formalin and then
analyzed by flow cytometer. The stained cells were gated based on
forward and side scatters and pulse width. At least 30,000 gated
events were analyzed using Summit Data Acquisition and Analysis
Software (DakoCytomation) as previously described [35]. MDBK
cells infected similarly with the respective viruses were stained by
FITC-conjugated mouse IgG2a and used as the isotype controls.
Results
Construction and characterization of BHV-1 UL49.5
CT-null virus and UL49.5 luminal domain mutants
We constructed a BHV-1 UL49.5 CT-null mutant virus by
deletion of two predicted amino acid residues 80RL81 encoded by
nt 238-AGGCTCA-244 (Fig. 1A and Fig. S1). In addition, nt
246GG247 were mutated to AA thereby incorporating a strong
stop codon, TAA immediately downstream of the predicted aa
residue 79F (Fig. 1A and Fig. S1).
Based on an alignment of predicted amino acid sequences of
UL49.5 luminal domains of several animal alpha herpesviruses;
BHV-1, pseudorabiesvirus (PRV, Accession No. U38547.1),
equine herpesvirus 1 type (EHV-1, Accession No. AY665713.1),
equine herpesvirus type 4 (EHV-4, Accession No. NC_001844),
and canine herpesvirus (CHV, Patent EPO 910406), we noticed
that a BHV-1 luminal domain motif UL49.5 30-RXEXXXX-
FW-XXXCXXXG-46 is conserved within the corresponding
UL49.5 luminal domains of several alpha herpesviruses (Fig. 1B).
To determine whether any of these conserved sequences are
functionally important for TAP inhibition, we designed and con-
structed BHV-1 UL49.5 luminal domain mutants (UL49.5D30–32,
UL49.5D37–40 and UL49.5D43–46) initially, in the BHV-1
UL49.5-CT null backbone (Fig. 1C). To determine the role of
residues 30–32 alone in TAP inhibition and TAP degradation,
we constructed both UL49.5D30–32 and alanine exchanged
(UL49.5 30AAA32) mutants, later, in the BHV-1 wt backbone
(Fig. 1D).
BAC excised BHV-1 UL49.5 mutant viruses were analyzed by
immuno-precipitation and/or immunoblotting to determine
molecular mass and level of mutant UL49.5 expression, incor-
poration of the mutant UL49.5 in the envelope and effect of
UL49.5 mutation on gM processing or UL49.5/gM interaction.
As shown in Figure 2A, relative to wt UL49.5 (approx. molecular
mass 10 kDa), molecular mass of the CT-null UL49.5 is approx.
8 kDa, which is consistent with the predicted molecular mass of
UL49.5 lacking C-terminal 17 aa residues. BHV-1 UL49.5D30–32
CT-null, UL49.5D37–40 CT-null, UL49.5D43–46 CT-null, and
UL49.5 30AAA32 CT-null viruses all have a UL49.5 with
molecular mass of approx. 8 kDa which are similar to the
parental virus BHV-1 UL49.5 CT-null. However, the BHV-1
UL49.5D30–32 and UL49.5 30AAA32 have an approx. molecular
mass of 10 kDa similar to wt UL49.5 (Fig. 2). Importantly, all
mutant UL49.5 proteins were incorporated into their respective
virion envelopes (Fig. 2).
Figure 2. Immunoblotting analysis of mutant UL49.5 expressed
in the infected cells and incorporated in the virion envelope by
various UL49.5 mutant viruses. Uninfected (Mock), BHV-1 wt- or
various mutant virus infected cell lysates or partially purified virions
were separated by a 10–20% gradient SDS-PAGE and incubated with
diluted (1:400) rabbit anti-BHV-1 a-U L49.5 specific antibodies. Equal
amounts of the extracted cell lysates or virions were loaded, and the a–
tubulin was used as a control.
doi:10.1371/journal.pone.0025742.g002
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rabbit polyclonal antibodies showed that i) amounts of wt and
mutant UL49.5 CT-null, UL49.5D30–32 CT-null, UL49.5D43–46
CT-null, and UL49.5D37–40 CT-null) immunoprecipitated by
anti UL49.5 antibody in each case were very similar (Fig. 3), ii) the
amount and molecular mass of mature gM coimmunoprecipi-
tated by the anti UL49.5 antibody from infected cell lysates of
BHV-1 wt, BHV-1 UL49.5 CT-null, BHV-1 UL49.5D30–32 CT-
null, and BHV-1 UL49.5D43–46 CT-null viruses were very
similar but in the case of BHV-1 UL49.5D37–40 CT-null, the
amount of processed (mature) gM coimmunoprecipitated was
reduced (Fig. 3), and iii) consistent with the latter results, with the
exception of BHV-1 UL49.5D37–40 CT-null, anti gM antibody
coimmunoprecipitated similar amounts of UL49.5 from the all the
virus-infected cell lysates. In the case of BHV-1 UL49.5D37–40
CT-null, the amount of UL49.5 coimmuno-precipitated was
slightly reduced and additionally, there was an increase in the
amount of unprocessed gM (pgM) (Fig. 3).
Taken together, these results indicated that the mutant viruses
have essentially normal UL49.5 expression and all but one mutant
(UL49.5D37–40 CT-null) have a normal gM processing and
UL49.5/gM interaction. The BHV-1 UL49.5D37–40 CT-null virus
has slightly defective gM processing and UL49.5/gM interaction.
Growth characteristics of reconstituted UL49.5 mutant
viruses in vitro in MDBK cells
The results of average plaque sizes (Figure 4A) and one step
growth kinetics (Figure 4B) showed that all BHV-1 UL49.5
mutants had virtually similar plaque sizes and growth kinetics
when compared with BHV-1 wt.
Peptide transport in BHV-1 UL49.5 mutant virus-infected
cells
Peptide transport was assessed, in the presence (Fig. 5A and B)
and absence of ATP (data not shown), in mock-infected MDBK
cells and MDBK-UL49.5
+ cells or infected with BHV-1 wt, BHV-
1U L49.5 CT-null and individual BHV-1 UL49.5 mutant viruses.
At 5hpi the effect of UL49.5 mutations on peptide transport in
BHV-1 UL49.5 mutant virus-infected cells relative to BHV-1 wt-
infected cells was noticeable (Fig. 5A), but the effects were more
prominent at 8 hpi (Fig. 5B). Relative to peptide transport in
BHV-1 wt-infected MDBK cells at 8hpi, peptide transport in cells
infected with: i) BHV-1 UL49.5D30–32 and BHV-1 UL49.5
30AAA32 was increased 4 fold (23% and 27% inhibition,
respectively versus 84% inhibition for the wt; P,0.01) ii) BHV-1
UL49.5 CT-null was increased 2.5 fold (63% inhibition versus
84% for the wt; P,0.05), and iii) BHV-1 UL49.5D30–32 CT-null
or BHV-1 UL49.5 30AAA32 CT-null was increased to approx. 6
folds (7% and 10% inhibition, respectively versus 84% for the wt;
P,0.01) (Fig. 5B). Since there was also an additional 1.2–1.5 fold
increase of peptide transport in BHV-1 UL49.5D30–32 CT-null-/
BHV-1 UL49.5 30AAA32 CT-null-infected cells compared
with the corresponding BHV-1 UL49.5D30–32/BHV-1 UL49.5
Figure 3. Analysis of gM-UL49.5 interaction by radioimmuno-
precipitation assay (RIPA).
35S labeled lysates from the mock-
infected or virus-infected MDBK cells were immunoprecipitated with
undiluted rabbit anti UL49.5- (A) or anti gM-specific polyclonal
antibodies (B) and separated by SDS-PAGE and visualized by
autoradiography. Unprocessed gM (pgM, marked with an arrow) and
processed gM (gM) are marked.
doi:10.1371/journal.pone.0025742.g003
Figure 4. Plaque morphology and growth kinetics of BHV-1
UL49.5 mutants in MDBK cells. (A) Plaque sizes produced by BHV-
1 wt, and various BHV-1 UL49.5 mutant viruses were measured at 48
hpi. Average plaque diameters of 50 randomly selected plaques are
shown as mean 6 standard deviation. (B) One-step growth kinetics of
BHV-1 wt, three representative BHV-1 UL49.5 mutants (UL49.5 D30–32,
UL49.5 D37–40 and UL49.5D43–46) in the CT-null backbone. Note that
BHV-1 UL49.5D37–40 CT-null exhibited slightly delayed viral replication
kinetics between 12 to 42 hpi. Each data point represents the average
of duplicate samples obtained from separate infections.
doi:10.1371/journal.pone.0025742.g004
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respectively)(Fig. 5), the increase in peptide transport due to the
UL49.5 CT sequence deletion alone was also significant (P,0.05).
As expected, in the absence of ATP there was no peptide transport
in wt and mutant viruses-infected MDBK cells (data not shown).
Regardless of BHV-1 UL49.5 D30–32 or BHV-1 UL49.5D30–
32 CT-null or BHV-1 UL49.5 CT-null virus infection, at 8hpi,
peptide transport in infected MDBK UL49.5
+ cells (Fig. S2) was
inhibited to almost wt UL49.5 level (,90%) (Fig. 5B). Therefore,
the relative increase in peptide transport in MDBK cells infected
with BHV-1 UL49.5 mutants with residues 30–32-deleted or
substituted with alanine and BHV-1 UL49.5 CT-null virus is due
to the lack of UL49.5 residues important for TAP mediated
peptide transport function.
MHC class I cell-surface expression in BHV-1 UL49.5
mutants-infected cells
As shown in Fig. 6A, compared with MHC-I cell surface
expression in mock-infected MDBK cells, there was reduced
MHC-1 expression in cells infected with BHV-1 wt and BHV-1
UL49.5 CT-null viruses but not when cells were infected with
BHV-1 UL49.5 D30–32 CT-null virus (Fig. 6A). As shown in
Figure 6B, compared with BHV-1 wt-infected MDBK cells,
MHC-I surface expression in: i) BHV-1 UL49.5D30–32- and
Figure 5. Analysis of TAP peptide transport function in various BHV-1 UL49.5 mutant-infected cells. The mock-, BHV-1 wt or various
BHV-1 UL49.5 mutant virus-infected MDBK cells (10 MOI) were harvested at 5 hpi (A) and 8 hpi (B) to perform peptide transport assays as described in
the materials and methods. The percentage above the bars denotes the decreased peptide-specific FITC intensity for each sample when compared
with the mock-infected cells, and the statistical significance is indicated by stars: *, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0025742.g005
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fold (74.3% and 75.0%, respectively versus 36.2% for the wt;
P,0.01) ii) BHV-1 UL49.5 D30–32 CT-null- and BHV-1 UL49.5
30AAA32 CT-null-infected MDBK cells was increased 2.5 fold
(88.6% and 89.1%, respectively versus 36.2% for the wt; P,0.01)
and iii) BHV-1 UL49.5 CT-null-infected cells was increased by 1.3
fold (49.6% versus 36.2% for the wt; P,0.05). Since a similar 1.2–
1.3 fold increase in MHC-I surface expression was also obtained in
BHV-1 UL49.5D30–32 CT-null-/BHV-1 UL49.5 30AAA32 CT-
null- compared with BHV-1 UL49.5D30–32/BHV-1 UL49.5
30AAA32 –infected cells (88.6%/89% versus 74.3%/75%), the
increase in MHC-I expression due to the deletion of UL49.5 CT
sequences alone was also significant (P,0.05).
In MDBK UL49.5
+ cells, regardless of BHV-1 UL49.5 CT-null
or BHV-1 UL49.5D30–32 CT-null virus infection, MHC-I cell-
surface expression was down-regulated like in wt BHV-1-infected
MDBK cells (Fig. 6B). Therefore, the relative increase in MHC-I
surface expression observed for the mutant viruses is due to the
effect of specific UL49.5 mutation(s) and is consistent with the
peptide transport data obtained for respective mutants with wt or
UL49.5 CT-null backgrounds.
Taken together, even though UL49.5 residues 30–32 are
essential for TAP mediated peptide transport/MHC-I down-
regulation, UL49.5 CT residues are important to express full
potential of UL49.5 mediated TAP inhibition and MHC-I down-
regulation function.
Status of TAP 1 molecules in the BHV-1 wt versus BHV-1
UL49.5 CT-null, BHV-1 UL49.5D30–32CT-null, BHV-
1UL49.5D30–32 and BHV-1 UL49.5 30-AAA32 mutants-
infected cells
Previously, we reported that in BHV-1 UL49.5 CT-null virus-
infected cells, TAP1 is not degraded [24]. In this study, the effect
of UL49.5D30–32, UL49.5D30–32 CT-null, UL49.5 30AAA32
and UL49.5 30AAA32 CT-null mutations on the status of TAP1 in
the respective mutant virus-infected cells was determined and
compared with the effect of UL49.5 CT-null and wt UL49.5 on
TAP1 degradation (Fig. 7). Since TAP1 was degraded only in
BHV-1 wt infected MDBK cells but not in BHV-1 UL49.5 CT-
null-, BHV-1 UL49.5D30–32, BHV-1 UL49.5 30AAA32, BHV-1
UL49.5D30–32 CT-null and BHV-1 UL49.5 30AAA32 CT-null-
Figure 6. FACS analysis of MHC-I surface expression on various BHV-1 UL49.5 mutant-infected cells. Infected MDBK cells or UL49.5
expressing MDBK-UL49.5+ cells were stained with anti-MHC-I Ab, subsequently incubated with FITC-conjugated rat anti-mouse IgG and subjected to
FACS analysis. A. Representative FACS histograms show the amount/profile of MHC-I expression in the mock-, BHV-1 wt-, BHV-1 UL49.5 CT-null- and
BHV-1 UL49.5D30–32 CT-null-infected cell surface. Normal mouse IgG2a served as an isotype-matched control (filled curve). B. Results shown are the
mean of three independent experiments of MHC-I expression on the MDBK cells or MDBK-UL49.5+ cells infected with BHV-1 wt, or various BHV-1
UL49.5 mutant viruses. The statistical significance is indicated by stars: *, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0025742.g006
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UL49.5 cytoplasmic tail sequences are equally important for
UL49.5-mediated TAP degradation.
Sub-cellular localization of wt and mutant UL49.5 in virus-
infected cells
To determine the sub cellular localization of the mutant UL49.5
CT-null, UL49.5D30–32 CT-null and UL49.5D30–32 proteins
relative to wt UL49.5 in the virus-infected cells and to determine
the status of TAP 1 degradation and TAP1 co-localization with the
mutant UL49.5, confocal microscopy was performed. The results
showed that at 12 hpi, TAP1 was not detectable in wt-infected
cells but TAP1 molecules were detectable in the ER of UL49.5
CT-null- , UL49.5D 30–32 CT-null- and UL49.5D30–32- infected
cells (Fig. 8). Nevertheless, at 6 hpi minor amounts of TAP1 were
detectable in the ER of BHV-1 wt-infected MDBK cells which
colocalized with UL49.5 (data not shown).
Considering the TAP1 degradation, peptide transport, MHC-I
down-regulation, and UL49.5-TAP1 co-localization data, we can
conclude that TAP1 and UL49.5 residues 30–32 interaction in the
ER is sufficient to inhibit TAP mediated peptide transport
function. However, both UL49.5 residues 30–32 and the UL49.5
CT residues are required for maximum UL49.5 inhibition of TAP
function.
Discussion
Previous studies reported that following BHV-1 infection, TAP
function was inhibited and as a consequence MHC-I surface
expression was down-regulated [10,11]. Our results from a recent
study using a cytoplasmic tail truncated BHV-1 UL49.5Am80
virus confirmed this finding and further demonstrated that BHV-1
UL49.5Am80 did not degrade TAP molecules but retained TAP
inhibition/MHC-I down-regulation functions in infected MDBK
cells [15]. Therefore, the results implied that the functional
domain required for TAP inhibition/MHC-I down-regulation
maps elsewhere within UL49.5. We then constructed two BHV-1
UL49.5 transmembrane domain-deleted mutants (BHV-1
UL49.5D55–66 and BHV-1 UL49.5D 67–79) and determined that
in both cases mutant UL49.5 protein affected gM processing, and
that both viruses had defective replication properties (data not
shown). Additionally, we and others (Wiertz, personal communi-
cation) found that the mutant UL49.5 versions lacking the
transmembrane domain residues were not stable and were
degraded (data not shown).
In this study, we constructed BHV-1 UL49.5 luminal domain
mutants in the wt UL49.5 or UL49.5 CT-null backgrounds and
determined their TAP inhibition, TAP degradation and MHC-I
down-regulation properties in virus-infected MDBK cells relative
to mock- and BHV-1 wt-infected MDBK cells. Further, we
determined the effects of UL49.5 mutations that abolished the
UL49.5-mediated TAP inhibition/MHC-I down-regulation func-
tions (BHV-1 UL49.5D 30–32 CT-null) on virus replication and
UL49.5/gM interaction. The salient features of our analyses were
as follows: i) Relative to wt-infected cells, cells-infected with
UL49.5 mutants having residues 30–32 deleted or substituted with
alanine have significantly increased TAP mediated peptide
transport and MHC-I surface expression. However, when BHV-
1U L49.5D30–32 mutation is combined with deletion of the
UL49.5 CT residues, there was a small but significant additional
increase in peptide transport and MHC-I surface expression, ii)
deletion of UL49.5 residues 30–32 or UL49.5 CT-null mutation
individually prevented UL49.5-mediated bovine TAP 1 degrada-
tion iii) BHV-1 UL49.5D 30–32 mutant virus replicated with wild-
type efficiency in MDBK cells and iv) UL49.5D30–32/gM
interaction and gM processing in mutant virus-infected cells were
not affected.
Recently, using Baculovirus and/or transiently expressed
mutant UL49.5 proteins, it was reported that deletion of UL49.5
luminal domain residues 23–32 or UL49.5 cytoplasmic tail
residues 94–96 can prevent UL49.5-mediated human TAP
degradation. However, UL49.5 luminal domain residues 28–32
alone are necessary for UL49.5 mediated human TAP inhibition
and down-regulation of human MHC-I surface expression [24].
Based on our sequence alignments of the UL49.5 luminal domains
of Varicelloviruses, including BHV-1, PRV, EHV-1 and EHV-4, we
noticed a conserved motif UL49.5 30-RXEXXXXFWXXXC-
XXXG-46. Therefore, we questioned their functional relevance, in
vitro, in the context of BHV-1-infected MDBK cells relative to the
results obtained above with Baculovirus expressed UL49.5.
Initially, we constructed several UL49.5 luminal domain mutants
in which either residues 30–32 (RRE) or 37–40 (FWSA) or 43–46
(YARG) were deleted in the background of a UL49.5 CT-null
virus and analyzed their effect on gM processing and interaction
with gM. Most importantly, their TAP inhibition/MHC-I down-
regulation properties were analyzed in comparison to wt UL49.5
and UL49.5 CT-null.
The results indicated that while increases in TAP-mediated
peptide transport and MHC-I cell-surface expression in BHV-1
UL49.5 CT-null infected MDBK cells were significant when
compared with BHV-1 wt, additional deletion of BHV-1 UL49.5
residues 30–32 (RRE) resulted in even further significant increases
in peptide transport and MHC-I cell surface expression when
compared with BHV-1 wt and BHV-1 UL49.5 CT-null. Subse-
quently, we introduced the UL49.5D30–32 deletion or UL49.5
30AAA32 substitutions in BHV-1 wt and determined their TAP
Figure 7. Immunoprecipitation/immunoblotting analysis of
cellular TAP1. Mock- or various virus-infected cell lysates were
immunoprecipitated with undiluted goat anti-bovine TAP1 specific
antibody followed by immunoblotting with diluted (1:200) rabbit anti-
TAP1 polyclonal serum, and then developed by enhanced chemilumi-
nescence. A ,70 kDa TAP1 specific band is detectable in the mock-,
BHV-1 UL49.5 CT-null-, BHV-1 UL49.5D30–32 CT-null, BHV-1 UL49.5
30AAA32 CT-null-, BHV-1 UL49.5D30–32-, and BHV-1 UL49.5 30AAA32-
infected cell lysates, but not in the case of BHV-1 wt. Note that in case
of BHV-1 wt virus-infected lysate TAP1-specific ,70 kDa band is mostly
degraded. A 45 kDa (approx.) non-specific protein is also immunopre-
cipitated and recognized in the immunoblot by the TAP1-specifc
antibodies in all the samples including the BHV-1 wt. Relative amount of
45 kDa protein immunopreciptated from each cell lysate sample can be
viewed as loading control.
doi:10.1371/journal.pone.0025742.g007
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tions in comparison to wt UL49.5 and UL49.5 CT-null. Based on
the results, deletion or alanine exchange of UL49.5 residues 30–32
or UL49.5 lacking the CT residues alone prevented UL49.5-
mediated bovine TAP 1 degradation. Relative to wt UL49.5 or
UL49.5 CT-null, there was a significant increase in peptide
transport and MHC-I cell surface expression in UL49.5 30–32
alanine substitution or deletion mutations in the wt background.
Nevertheless, peptide transport and MHC-I surface expression was
increased even more when UL49.5 D30–32 and UL49.5 30AAA32
mutations were introduced in the UL49.5-CT null background.
When MDBK cells expressing the wt UL49.5 were infected with the
BHV-1 UL49.5-CT null-, BHV-1 UL49.5D30–32 and BHV-1
UL49.5 30AAA32 mutant viruses, the inhibition of peptide
transport and down- regulation of MHC-I cell surface expression
of the mutant viruses were restored to the BHV-1 wt levels. Taken
together, the results of TAP1 degradation, peptide transport
inhibitory and MHC-I down-regulatory property of the BHV-1
UL49.5 CT-null, BHV-1 UL49.5D30–32, BHV-1 UL49.5
30AAA32 mutants in MDBK cells and MDBK cells expressing
wt UL49.5, we conclude that i) UL49.5 residues 30–32 (RRE) and
UL49.5 CT residues (80–96) both are important for TAP1
degradation, ii) even though primary TAP inhibition domain lies
in UL49.5 30–32 residues, the fullest extent of UL49.5 mediated
TAP inhibition function additionally required the UL49.5 cytoplas-
mic tail (CT) residues. Similarly, the fullest extent of UL49.5-
mediated down-regulation of MHC-I cell surface expression
required both the UL49.5 luminal domain residues 30–32 and the
UL49.5 CT residues.
Our results, in general, are in agreement with the results of
Baculovirus expressed UL49.5 in a transient expression system,
especially with respect to UL49.5 sequences important for TAP
degradation [24]. However, our results differed with respect to
TAP inhibition and MHC-I surface expression [24]. Our TAP
inhibition results showed that even though UL49.5 residues 30–32
are essential for TAP inhibition/MHC-I down-regulation func-
tions, the fullest extent of UL49.5 mediated TAP inhibition and
MHC-I down-regulation additionally required the UL49.5 cyto-
plasmic tail (CT) residues. In summary, the UL49.5 residues 30–32
and UL49.5 CT residues together inhibit peptide transport and
down- regulate MHC-I cell surface expression.
Previously, Loch et al [24] reported that UL49.5 D23–32
neither inhibited nor degraded the TAP. Additionally, they
reported that like the deletion of entire UL49.5 CT, deletion of
two residues 95RG96 at the C terminus failed to induce
proteosomal degradation of the TAP complex. Based on a
Figure 8. Analysis of TAP1 and mutant UL49.5 co-localization in the ER of BHV-1 wt- and BHV-1 UL49.5 mutant virus-infected cells.
Mock-, BHV-1 wt (WT), BHV-1 UL49.5 CT-null, BHV-1 UL49.5D30–32 CT-null and BHV-1 UL49.5D30–32-infected MDBK cells were fixed at 12 hpi,
permeabilized, and incubated with the cocktail of antibodies (goat anti-bovine TAP1, rabbit anti UL49.5, and chicken anti-Calreticulin/ER-specific).
After washing, the samples were further incubated with cocktail of secondary antibodies (Alexa Flour 488-conjugated donkey anti goat, Alexa 350-
conjugated donkey anti-chicken and Alexa flour 594-conjugated donkey anti rabbit). Note that TAP was not detectable in the ER of BHV-1 wt-infected
cells. Mock-infected MDBK cells served as controls.
doi:10.1371/journal.pone.0025742.g008
BHV-1 UL49.5 Residues Important for TAP-Inhibition
PLoS ONE | www.plosone.org 9 October 2011 | Volume 6 | Issue 10 | e25742conserved RXE motif in the corresponding UL49.5/gN regions of
BHV-1, EHV-1 and PRV, they predicted that the RXE motif
might be important for these functions. Our results proved that the
conserved RXE motif is indeed important for BHV-1 UL49.5 TAP
inhibition and TAP degradation functions. Previous studies
predicted that wt UL49.5 binds to TAP complex through its
transmembrane domain, and that the binding of wt UL49.5 leads
to conformational arrest of TAP complex [24]. Subsequently, the
luminal domain RXE motif signaling to the C-terminal residues
95RG96 across the ER membrane is necessary for triggering the
degradation of the TAP complex. In this study, our results
demonstrated that in the absence of either UL49.5 luminal domain
residues RXE or CT residues, TAP is not degraded. Therefore,
both the sequence elements are equally important for the UL49.5
mediated TAP degradation. Based on our results on TAP
inhibition, it is also reasonable to predict that both the RRE
motif and the CT may communicate in a similar fashion, noted
above, to cause efficient UL49.5 mediated TAP inhibition
synergistically. However, they are not equally important for
TAP inhibition because deletion of RXE motif had significantly
higher TAP inhibition compared to CT-null. Interestingly enough,
a BLAST search (program BLASTP 2.2.25+) of NCBI protein
data bank revealed that similar RRE/RXE motif is highly
conserved in a number of bacterial proteins important for ATP
dependent enzymatic activity, transcriptional regulator, GTP and
ATP binding proteins (Fig. 9). Currently, it is not known whether
the highly conserved RXE motifs in any of the proteins listed in
Fig. 9 actually binds to ATP or are required for their ATP
mediated functions. Recently, it was reported that BHV-1 UL49.5
does not interfere with binding of ATP to TAP. However, EHV-1
UL49.5 containing similar RXE motif inhibits TAP by interfering
with ATP binding to TAP. It remains to be seen whether the RXE
motif in EHV-1 UL49.5 binds to ATP directly or interacts
indirectly to prevent ATP binding to TAP. Loch et al [24]
suggested that BHV-1 UL49.5 inhibits TAP primarily by
degrading TAP. While that might the case for the wt UL49.5
where TAP is degraded, retention of significant TAP inhibition
property of UL49.5 lacking the CT where TAP is not degraded,
requires an alternative mechanism of TAP inhibition. Taken
together, our results in this study and since the motif is highly
conserved in the enzymatically active proteins requiring ATP or in
ATP binding proteins, we predict that in the absence of CT
residues, UL49.5 luminal domain RRE motif may interact with or
compete in some fashion for ATP binding to TAP and blocks the
peptide transport. This needs to be tested in future studies.
Both in BHV-1 and EHV-1, UL49.5 (gN homolog) is not
glycosylated but UL49.5/gM interaction is required for gM
processing in the Golgi [21,22,23]. In PRV, gN is glycosylated but
is not required for gM processing [20]. The analyses of mutant
UL49.5 proteins’ interaction with gM and their effect on gM
processing showed that only the mutant UL49.5 D37–40 CT-null
had slightly defective gM processing and mutant UL49.5/gM
interaction. Recently, we have determined that alanine exchange
mutation of BHV-1 UL49.5 residue C42A affected mutant UL49.5
interaction with the gM and gM processing in the Golgi but not
the TAP inhibition function of UL49.5 (Wei and Chowdhury,
manuscript in preparation). Since UL49.5 CT-null mediated TAP
inhibition function was not affected due to the additional deletion
of residues 37–40 and because residue C42 is important for gM
binding and not for TAP inhibition (Wei and Chowdhury,
manuscript in preparation), we conclude that UL49.5 TAP
inhibition and gM interaction domains are different and do not
overlap.
Since the mutant UL49.5D30–32 CT-null interaction with the
gM and gM maturation was unaffected, and the mutant UL49.5
was incorporated in the virion envelope, we interpreted that
mutant UL49.5 protein conformation was not affected. Results
from a recent calf experiment indicated that immunogenicity of
and cellular immunity against BHV-1 UL49.5D30–32 CT-null
mutant virus was enhanced when compared with wt BHV-1 (Wei
and Chowdhury, in submission). Therefore, by incorporating these
UL49.5 mutations in a future BHV-1 marker vaccine we could
improve the vaccine efficacy of the current BHV-1 gE-deleted
marker vaccine.
Figure 9. Alignment of the RXE consensus motif obtained from a BLAST search of the NCBI protein data bank. GenBank accession
numbers are listed within parenthesis. ATP-dependent DNA helicases in R. jostii (ABG98153.1), R. opacus (BAH54685.1), M. kansasii (ZP_04750796.1)
and R. equi (CBH49273.1). ATP-binding protein of abc transport system in C. bacterium (EDZ61139.1). Phosphoglucosamine mutase in D. desulfuricans
subsp (ACL49611.1). enoyl-CoA hydratase in B. ubonensis (ZP_02380855.1), elongation factor 3 in P. tritici-repentis (EDU48512.1), regulatory protein
Ada in A. thermophila (BAJ64916.1), transcriptional regulator in Micromonospora sp. (EEP74779.1), PadR-like family transcriptional regulator in Opitutus
terrae (ACB77801.1), winged helix family two component transcriptional regulator in B. sp. (ADX58638.1), GTP-binding protein TypA in W.
chondrophila (ADI37545.1).
doi:10.1371/journal.pone.0025742.g009
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Figure S1 DNA Sequences of wild type BHV-1 UL49.5.
To generate BHV-1 gN CT-null, the nucleotides 238 to 244 were
deleted and the nucleotides 246 and 247 are mutated to AA to
introduce a strong stop codon TAA.
(TIF)
Figure S2 Immunoblotting analysis of MDBK UL49.5+
cells expressing BHV-1 UL49.5. As a control, mock and
BHV-1 wt-infected MDBK cell lysates were immunoblotted with
rabbit anti BHV-1 UL49.5-specific antibody (1:400).
(TIF)
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